Streetbeat News

Regulatory

SPY

VGK

The European Central Bank (ECB) has decided to leave interest rates unchanged, maintaining its current monetary policy stance. This decision comes amid ongoing economic uncertainties in the Eurozone.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:15 pm

CLDI

Calidi Biotherapeutics (NYSE:CLDI) has received a new U.S. patent for its SuperNova technology platform, enhancing its intellectual property and advancing its CLD-201 program.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:12 pm

PHAT

The FDA has approved Phathom Pharmaceuticals' Voquezna (Vonoprazan) 10 mg tablets for treating heartburn associated with non-erosive gastroesophageal reflux disease in adults. This marks the third FDA approval for Voquezna.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:10 pm

COCP

Cocrystal Pharma, Inc. (NASDAQ:COCP) reported favorable safety and tolerability results from the single-ascending dose cohorts of its Phase 1 study with CDI-988, an oral pan-viral protease inhibitor targeting norovirus and coronaviruses.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:08 pm

AAPL

Apple Inc. (NASDAQ:AAPL) has denied using YouTube videos to train its AI features, clarifying that its OpenELM model is solely for research purposes. This follows reports of tech companies using YouTube subtitles for AI training without consent. Apple emphasized that its AI models are trained on licensed and publicly available data.

Portfolio Pulse from Rounak Jain

July 18, 2024 | 12:07 pm

AGEN

Agenus shares are trading lower following the announcement of results from its end-of-Phase 2 meeting with the FDA regarding its immunotherapy combination for colorectal cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:53 am

KARS

KGRN

NIO

NIO Inc. (NYSE:NIO) shares are trading higher in the premarket session following the confirmation of the upcoming release of the NIO Phone, which has obtained China Compulsory Certificate (CCC) certification. The phone, manufactured by Lens Technology, integrates with NIO vehicles and is part of NIO's strategy to enhance vehicle appeal. NIO shares have lost over 45% year to date. Investors can also gain exposure to NIO via KraneShares MSCI China Clean Technology Index ETF (NYSE:KGRN) and KraneShares Electric Vehicles And Future Mobility Index ETF (NYSE:KARS).

Portfolio Pulse from Nabaparna Bhattacharya

July 18, 2024 | 11:51 am

VIGL

Vigil Neuroscience announced an update to its clinical development strategy for the IGNITE trial of iluzanebart following a Type C meeting with the FDA. The final analysis, including all patients dosed at 12 months, will be reported in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:18 am

MRNS

China National Medical Products Administration has approved Marinus Pharmaceuticals' Ganaxolone oral suspension for treating epileptic seizures in patients aged two years and older with CDKL5 deficiency disorder.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:09 am

AGEN

Agenus announced the outcomes of its End-of-Phase-2 meeting and topline interim Phase 2 data for its BOT/BAL combination. The company has reached an agreement with the FDA on the Phase 3 dose for this combination.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 11:07 am